GiulianiJBonettiA. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res2019; 39: 3971–3973.
2.
PanjeCMLupatschJEBarbierM, et al.A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Ann Oncol2010; 31: 501–506.
3.
AntoniaSJVillegasADanielD, et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med2017; 377: 1919–1929.
4.
AntoniaSJVillegasADanielD, et al.Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med2018; 379: 2342–2350.
5.
ChernyNISullivanRDafniU, et al.A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol2015; 26: 1547–1573.
6.
GiulianiJBonettiA. Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American society of clinical oncology annual meeting, 2018. Eur J Cancer. 2018; 104: 233–235.
7.
AzimiNAWelchHG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med1998; 13: 664.
8.
GiulianiJBonettiA. Financial toxicity and non-small cell lung cancer treatment: the optimization in the choice of immune check point inhibitors. Anticancer Res2019; 39: 3961–3965.
9.
GiulianiJBonettiA. Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice?Recenti Prog Med2019; 110: 138–143.
10.
GiulianiJBonettiA. Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. Oral Oncol2019; 97: 143–145.
11.
GiulianiJBonettiA. Nivolumab in second-line treatment for advanced non-small-cell lung cancer with squamous-cell histology: a perspective based on pharmacologic costs. Clin Lung Cancer2017; 18: e363–e365.
12.
GiulianiJBonettiA. Nivolumab Is a cost-effective second-line treatment for metastatic renal-cell carcinoma. Clin Genitourin Cancer2018; 16: e557–e562.
13.
GiulianiJAlbaneseVPonturoG,et al.Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life. J Oncol Pharm Pract2019; 25: 2059–2060.
14.
HancockCGreenLLestingiT,et al.An attempt to quantitate “value” in medical oncologic therapy. Cureus2018; 10: e2810.
15.
ArmeniPBorsoiLFornaroG,et al.Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the Italian national health service. Clin Ther2020; 42: 830–847.
16.
HanJTianKYangJ,et al.Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: an updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer2020; 146: 42–49.
17.
CrissSDMooradianMJSheehanDF,et al.Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the US health care system. JAMA Oncol2019; 5: 358–365.
